Patents by Inventor Giuseppe Claudio Viscomi

Giuseppe Claudio Viscomi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220241193
    Abstract: The invention relates to gel compositions comprising pharmaceutical active ingredients. The composition comprises xyloglucan at a concentration between 0.1% and 10.0% by total weight of the composition, together with a primary alcohol at a concentration between 20.0 and 50.0% by total weight of the composition. The invention also describes a process for the preparation of the composition and its use in the treatment of pathologies wherein a controlled release of the active principle is useful.
    Type: Application
    Filed: June 11, 2020
    Publication date: August 4, 2022
    Applicant: ALFASIGMA S.P.A.
    Inventors: Giuseppe Claudio Viscomi, Paola MAFFEI, Cristiana Bruno, Mascia Federici, Clelia Dispenza, Maria Antonietta Sabatino
  • Publication number: 20220127283
    Abstract: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin ? and rifaximin ?, and a poorly crystalline form named rifaximin ?, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
    Type: Application
    Filed: January 6, 2022
    Publication date: April 28, 2022
    Inventors: Giuseppe Claudio VISCOMI, Manuela CAMPANA, Dario BRAGA, Donatella CONFORTINI, Vincenzo CANNATA, Paolo RIGHI, Goffredo ROSINI, Denis SEVERINI
  • Publication number: 20220119410
    Abstract: Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin ? and rifaximin ?, and a poorly crystalline form referred to as rifaximin ?, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.
    Type: Application
    Filed: December 28, 2021
    Publication date: April 21, 2022
    Inventors: Giuseppe Claudio VISCOMI, Manuela CAMPANA, Dario BRAGA, Donatella CONFORTINI, Vincenzo CANNATA, Paolo RIGHI, Goffredo ROSINI, Denis SEVERINI
  • Publication number: 20220119403
    Abstract: Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin ? and rifaximin ? useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
    Type: Application
    Filed: December 28, 2021
    Publication date: April 21, 2022
    Inventors: Giuseppe Claudio VISCOMI, Manuela CAMPANA, Donatella CONFORTINI, Maria BARBANTI, Dario BRAGA
  • Patent number: 11241452
    Abstract: The present invention describes a mucoadhesive composition comprising chondroitin sulfate, xyloglucan and glycerol for use in the treatment and prevention of gastroesophageal reflux. It is also described a process for preparing such composition, a dosage form for its administration and a kit comprising the same.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: February 8, 2022
    Assignee: ALFASIGMA S.P.A.
    Inventors: Paola Maffei, Marco Mascagni, Giuseppe Claudio Viscomi
  • Publication number: 20210244714
    Abstract: Disclosed herein are methods of treating a patient having an intestinal disorder, the methods comprising: administering to a patient in need thereof a pharmaceutical composition comprising a hydrate or solvate form of rifaximin in polymorphic form ?, alone or in a mixture with other crystalline, hydrate, solvate or amorphous forms of rifaximin, in gastroresistant microgranules, wherein the rifaximin is administered at a dose of at least 800 mg per day for a period of at least 7 days.
    Type: Application
    Filed: September 17, 2020
    Publication date: August 12, 2021
    Applicant: ALFASIGMA S.P.A.
    Inventors: Giuseppe Claudio VISCOMI, Paola MAFFEI, Giuseppe BOTTONI, Maria GRIMALDI
  • Publication number: 20200339600
    Abstract: Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin ? and rifaximin ?, and a poorly crystalline form referred to as rifaximin ?, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.
    Type: Application
    Filed: July 14, 2020
    Publication date: October 29, 2020
    Inventors: Giuseppe Claudio VISCOMI, Manuela CAMPANA, Dario BRAGA, Donatella CONFORTINI, Vincenzo CANNATA, Paolo RIGHI, Goffredo ROSINI, Denis SEVERINI
  • Publication number: 20200339599
    Abstract: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin ? and rifaximin ?, and a poorly crystalline form named rifaximin ?, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
    Type: Application
    Filed: July 14, 2020
    Publication date: October 29, 2020
    Inventors: Giuseppe Claudio VISCOMI, Manuela CAMPANA, Dario BRAGA, Donatella CONFORTINI, Vincenzo CANNATA, Paolo RIGHI, Goffredo ROSINI, Denis SEVERINI
  • Patent number: 10793925
    Abstract: The present invention refers to a new strain belonging to the species Lactobacillus paracasei able to convert linoleic acid into conjugated linoleic acid. The present invention refers also to nutritional or food preparations and/or pharmaceutical compositions, comprising the strain Lactobacillus paracasei, useful in the treatment and/or prevention of pathologies and/or physiological states related to conjugated linoleic acid deficiency or in the cases wherein the use of a probiotic is beneficial.
    Type: Grant
    Filed: October 1, 2019
    Date of Patent: October 6, 2020
    Assignee: ALFASIGMA S.P.A.
    Inventors: Giuseppe Claudio Viscomi, Annalisa Sforzini, Pierluigi Mangino, Marina Elli
  • Publication number: 20200277301
    Abstract: Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin ? and rifaximin ? useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
    Type: Application
    Filed: May 19, 2020
    Publication date: September 3, 2020
    Inventors: Giuseppe Claudio VISCOMI, Manuela CAMPANA, Donatella CONFORTINI, Maria BARBANTI, Dario BRAGA
  • Patent number: 10703763
    Abstract: Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin ? and rifaximin ? useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: July 7, 2020
    Assignee: ALFASIGMA S.P.A.
    Inventors: Giuseppe Claudio Viscomi, Manuela Campana, Donatella Confortini, Maria Barbanti, Dario Braga
  • Publication number: 20200032357
    Abstract: The present invention refers to a new strain belonging to the species Lactobacillus paracasei able to convert linoleic acid into conjugated linoleic acid. The present invention refers also to nutritional or food preparations and/or pharmaceutical compositions, comprising the strain Lactobacillus paracasei, useful in the treatment and/or prevention of pathologies and/or physiological states related to conjugated linoleic acid deficiency or in the cases wherein the use of a probiotic is beneficial.
    Type: Application
    Filed: October 1, 2019
    Publication date: January 30, 2020
    Applicant: ALFASIGMA S.P.A.
    Inventors: Giuseppe Claudio Viscomi, Annalisa Sforzini, Pierluigi Mangino, Marina Elli
  • Publication number: 20200002350
    Abstract: Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin ? and rifaximin ? useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
    Type: Application
    Filed: March 4, 2019
    Publication date: January 2, 2020
    Inventors: Giuseppe Claudio VISCOMI, Manuela CAMPANA, Donatella CONFORTINI, Maria BARBANTI, Dario BRAGA
  • Publication number: 20200000726
    Abstract: The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5:0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease.
    Type: Application
    Filed: April 9, 2019
    Publication date: January 2, 2020
    Inventors: Giuseppe Claudio VISCOMI, Ernesto PALAZZINI, Villiam ZAMBONI, Maria Rosaria PANTALEO
  • Publication number: 20190388411
    Abstract: Described herein are methods and systems for treatment and/or prevention of conditions associated with NSAID administration and related compositions.
    Type: Application
    Filed: June 28, 2019
    Publication date: December 26, 2019
    Inventors: Giuseppe Claudio VISCOMI, Maria GRIMALDI, Maria Vittoria FOGLI, Paola MAFFEI, Cecilia RENZULLI, Annalisa SFORZINI, Corrado BLANDIZZI, Carmelo SCARPIGNATO
  • Publication number: 20190314402
    Abstract: The present invention describes a mucoadhesive composition comprising chondroitin sulfate, xyloglucan and glycerol for use in the treatment and prevention of gastroesophageal reflux. It is also described a process for preparing such composition, a dosage form for its administration and a kit comprising the same.
    Type: Application
    Filed: September 18, 2018
    Publication date: October 17, 2019
    Applicant: ALFASIGMA S.P.A.
    Inventors: Paola Maffei, Marco Mascagni, Giuseppe Claudio Viscomi
  • Patent number: 10428086
    Abstract: The present invention describes a new crystalline form of rifaximin, characterized in that it is a solvated form of rifaximin called rifaximin ? The invention also describes a process for the preparation of rifaximin ?, a pharmaceutical composition comprising said rifaximin form, and its use for treating inflammations and infections.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: October 1, 2019
    Assignee: ALFASIGMA S.P.A.
    Inventors: Giuseppe Claudio Viscomi, Paola Maffei, Annalisa Sforzini, Fabrizia Grepioni, Laura Chelazzi
  • Publication number: 20190263829
    Abstract: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin ? and rifaximin ?, and a poorly crystalline form named rifaximin ?, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
    Type: Application
    Filed: May 10, 2019
    Publication date: August 29, 2019
    Inventors: Giuseppe Claudio VISCOMI, Manuela CAMPANA, Dario BRAGA, Donatella CONFORTINI, Vincenzo CANNATA, Paolo RIGHI, Goffredo ROSINI, Denis SEVERINI
  • Publication number: 20190263830
    Abstract: Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin ? and rifaximin ?, and a poorly crystalline form referred to as rifaximin ?, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.
    Type: Application
    Filed: May 10, 2019
    Publication date: August 29, 2019
    Inventors: Giuseppe Claudio VISCOMI, Manuela CAMPANA, Dario BRAGA, Donatella CONFORTINI, Vincenzo CANNATA, Paolo RIGHI, Goffredo ROSINI, Denis SEVERINI
  • Patent number: 10285944
    Abstract: The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: May 14, 2019
    Assignee: ALFASIGMA S.P.A.
    Inventors: Giuseppe Claudio Viscomi, Ernesto Palazzini, Villiam Zamboni, Maria Rosaria Pantaleo